Scientific Letters
Vol. 17 No. 1 (2025): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
A case of multiple myeloma in a patient in treatment for chronic lymphocytic leukemia
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: February 18, 2025
Accepted: April 10, 2025
Accepted: April 10, 2025
815
Views
620
Downloads
112
HTML
Authors
Synchronous and sequential diagnosis of Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) is a rare event with no cases described with a need for concomitant treatment for both diseases. Here we describe a case of a 58 years old male patient diagnosed with CLL and then MM, needing concomitant treatment for both diseases. We treated the patient with a BELLINI trial-like regimen including Bortezomib, Venetoclax and Dexamethasone, obtaining a good response for both the malignancies.
Downloads
Download data is not yet available.
Citations
How to Cite
“A case of multiple myeloma in a patient in treatment for chronic lymphocytic leukemia” (2025) Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025033. doi:10.4084/MJHID.2025.033.
Copyright (c) 2025 Mario Biglietto, Ugo Coppetelli, Luciano Fiori, Martina Gherardini, Raffaele Maglione, Alessandro Pulsoni, Azzurra Anna Romeo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
